A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

Objective: The proportion of patients with stage I lung adenocarcinoma (LUAD) has dramatically increased with the prevalence of low-dose computed tomography use for screening. Up to 30% of patients with stage I LUAD experience recurrence within 5 years after curative surgery. A robust risk stratific...

Full description

Bibliographic Details
Main Authors: Chengming Liu, Sihui Wang, Sufei Zheng, Xinfeng Wang, Jianbin Huang, Yuanyuan Lei, Shuangshuang Mao, Xiaoli Feng, Nan Sun, Jie He
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-08-01
Series:Cancer Biology & Medicine
Subjects:
lung adenocarcinoma
stage i
recurrence
metabolic signature
immune landscape
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1838

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1838

Similar Items